Weekly roundup: A multi-million dollar deal with Lilly and industry advances
Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company
Alchemab Therapeutics announced that it has entered into a $415m licensing agreement with Eli Lilly and Company for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. ATLX-1282 is the first programme out of Alchemab’s entirely novel platform, which generates and analyses millions of antibody sequences from resilient individuals.
Astraveus enters strategic partnership with NecstGen to evaluate Lakhesys Benchtop Cell FactoryTM for CAR-T therapy manufacturing
Astraveus announced that it has entered into a strategic partnership with The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen) to evaluate The Lakhesys Benchtop Cell FactoryTM for the manufacturing of CAR-T therapies. The partnership is to demonstrate the ability of Astraveus’ technology to deliver reduced costs and increased efficiency in CAR-T manufacturing.
iOnctura commences randomised Phase I/II study in non-small cell lung cancer
iOnctura announced it has dosed the first patient in a randomised Phase I/II study investigating its lead asset roginolisib in combination with dostarlimab with or without docetaxel, in patients with advanced non-small cell lung cancer (NSCLC). The study will evaluate the safety of the combination and explore whether targeting PI3Kδ with immunotherapy may rebalance the immune system to prevent or reverse resistance to current standard immunotherapy/chemo in NSCLC.
Vesper Bio achieves enrolment milestone in Phase Ib/IIa trial of lead candidate VES001 for frontotemporal dementia
Vesper Bio announced it has reached an important enrolment milestone in its Phase Ib/IIa SORT-IN-2 trial of its lead candidate, VES001. The trial has enrolled six asymptomatic carriers of a mutation in the progranulin-coding gene (GRN), which causes a leading genetically determined type of frontotemporal dementia (FTD), called FTD-GRN. VES001 is a first-in-class, oral, brain-penetrant small molecule sortilin inhibitor, which is being developed as a disease-modifying treatment for FTD-GRN.
Optimum TV
Most people have heard of Huntington’s disease – but not all will really know what it is. To mark Huntington’s Disease Awareness Month, David Reynolds, CEO of LoQus23 Therapeutics, talked to Optimum TV about its genetic underpinning, how it develops over time, symptoms, and modern treatment approaches. For a concise 8-minute primer, watch now!
Industry events
Bio€quity Europe is now just days away! Celebrating 25 years of this prestigious event, Optimum is proud to be sponsoring the networking breakfast. Please reach out if you would like to connect with our CEO Mary Clark, and Associate Director Zoe Bolt at the conference.
📍12 – 14 May, Bruges, Belgium
Sector moves
Keep up to date with the latest industry moves here.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
